Epstein Files Search

EFTA00598930Dataset 9

2015-10-025p4,184w

…high Ovenveighl Price: 549.37 PD-L1 expressers. As a result we see a healthy uptake of Keytruda in 2L PD-L1+ patients. 01 October 2015 • We expect the label to expand over time. With KEYNOTE-010, a registrational 2L study expected to read out in the next several months and different frontline studies ongoing in PD-L1+/ all comer patients, we expect the initial label to broaden over time and gradually increase Keytruda's footprint in NSCLC. In addition…

https://www.justice.gov/epstein/files/DataSet%209/EFTA00598930.pdf

EFTA00847263Dataset 9

2015-09-022p426w

Subject: Mrk

From: Richard KahnTo: Jeffrey Epstein [email protected]>

…Target Price: Neutral, S61 Potential Stock Upside: 11% Upcoming Catalyst: MRK's Januvia franchise will likely feel pressure from the positive EMPA-REG OUTCOME data but we expect MRK to get a boost from FDA approval of Keytruda in 2nd line NSCLC soon (FDA action date Oct 2) and its HCV doublet grazoprevir/elbasvir by early next year (FDA action date Jan 28). TheStreet Rating: Buy, B+ TheStreet Said: TheStreet Ratings team rates MERCK & CO as a Buy with a…

https://www.justice.gov/epstein/files/DataSet%209/EFTA00847263.pdf

EFTA00810760Dataset 9

2017-12-221p432w

…including experimental therapies. Dr. Watson also assessed how the loss of NF1 affects the function of other proteins in tumor cells. This research found NF1 regulates molecules that affect how the immune system functions, including influencing the production of a molecule that is a major target in several approved immune "checkpoint inhibitor" therapies, such as pembrolizumab (Keytruda). Dr. Watson and his research team are currently collaborating with several oncologists, dermatology pathologists, and surgeons at McGill University Health Center and the…

https://www.justice.gov/epstein/files/DataSet%209/EFTA00810760.pdf

EFTA00673207Dataset 9

2015-10-2534p11,593w

Subject: Greg Brown's Weekend Reading and Other Things.. 10/25/2015

From: Gregory BrownTo: undisclosed-recipients:;

…for oncology agents have nearly doubled in the past decade, from an average of $5000 per month to more than $10,000 per month. The price for cancer drugs like Yervoy, Opdivo and Keytruda routinely exceeds $120,000 a year. Some other specialty drugs have even higher prices. Cerezyme for Gaucher disease costs about $300,000 per year for life. Kalydeco for cystic fibrosis also costs about $300,000 per year. Despite representing about 1 percent of prescriptions in 2014…

https://www.justice.gov/epstein/files/DataSet%209/EFTA00673207.pdf

EFTA02712861Dataset 11

2014-09-2722p9,579w

Subject: Greg Brown's Weekend Reading and Other Things.... 09/28/2014

From: Gregory Brown <To: undisclosed-recipients:

…is no longer a death sentence as there are a number of cutting edge treatments that are allowing patients to beat this killer and enabling them to live productive lives for decades. Last w=ek I did a piece on the new immunotherapy drug Keytruda (pembrolizumab) which the U.S. Food and Drug Administration approved several weeks ago to t=eat patients who had advanced melanoma that had spread throughout their bodies,=signaling a paradigm shift in the way the deadly skin…

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02712861.pdf